Immunocore Holdings plc (NASDAQ:IMCR) Shares Sold by Bank of America Corp DE

Bank of America Corp DE decreased its holdings in shares of Immunocore Holdings plc (NASDAQ:IMCR - Free Report) by 33.5% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 189,577 shares of the company's stock after selling 95,362 shares during the period. Bank of America Corp DE owned 0.38% of Immunocore worth $5,593,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in IMCR. BNP Paribas Financial Markets purchased a new stake in Immunocore in the fourth quarter worth approximately $5,697,000. The Manufacturers Life Insurance Company raised its position in shares of Immunocore by 6.3% during the 4th quarter. The Manufacturers Life Insurance Company now owns 114,151 shares of the company's stock valued at $3,367,000 after purchasing an additional 6,760 shares during the period. Virtus ETF Advisers LLC raised its position in shares of Immunocore by 39.0% during the 4th quarter. Virtus ETF Advisers LLC now owns 11,536 shares of the company's stock valued at $340,000 after purchasing an additional 3,238 shares during the period. T. Rowe Price Investment Management Inc. increased its holdings in Immunocore by 3.1% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 6,700,208 shares of the company's stock valued at $197,657,000 after acquiring an additional 200,373 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its holdings in Immunocore by 1.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,187,530 shares of the company's stock valued at $64,533,000 after acquiring an additional 29,832 shares during the last quarter. Institutional investors own 84.50% of the company's stock.

Immunocore Stock Performance

Immunocore stock traded up $1.45 during mid-day trading on Friday, reaching $36.49. 817,284 shares of the company traded hands, compared to its average volume of 387,721. The company has a debt-to-equity ratio of 1.03, a current ratio of 3.78 and a quick ratio of 3.76. Immunocore Holdings plc has a fifty-two week low of $23.15 and a fifty-two week high of $48.50. The company has a market capitalization of $1.83 billion, a price-to-earnings ratio of -38.41 and a beta of 0.75. The firm's fifty day moving average is $29.37 and its two-hundred day moving average is $29.95.

Immunocore (NASDAQ:IMCR - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.10 EPS for the quarter, beating the consensus estimate of ($0.35) by $0.45. The business had revenue of $125.13 million for the quarter, compared to the consensus estimate of $108.82 million. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.84%. The business's revenue for the quarter was up 33.6% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.49) EPS. On average, equities research analysts expect that Immunocore Holdings plc will post -0.94 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. Mizuho reduced their target price on shares of Immunocore from $38.00 to $33.00 and set a "neutral" rating on the stock in a report on Monday, April 7th. Oppenheimer lifted their price target on shares of Immunocore from $85.00 to $86.00 and gave the stock an "outperform" rating in a research note on Thursday, May 8th. Needham & Company LLC reissued a "buy" rating and issued a $71.00 price objective on shares of Immunocore in a research report on Thursday, April 10th. Morgan Stanley reaffirmed an "equal weight" rating and issued a $35.00 price target on shares of Immunocore in a research report on Friday, March 7th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $100.00 price target on shares of Immunocore in a research report on Wednesday, March 12th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $58.89.

Insider Activity

In related news, Director Bros. Advisors Lp Baker acquired 807,338 shares of the firm's stock in a transaction on Monday, March 17th. The shares were acquired at an average cost of $29.72 per share, with a total value of $23,994,085.36. Following the completion of the acquisition, the director now directly owns 2,144,060 shares in the company, valued at approximately $63,721,463.20. This trade represents a 60.40% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 10.40% of the company's stock.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.